Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vera Therapeutics
< Previous
1
2
Next >
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 22, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
November 18, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
November 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate at Upcoming Investor Conferences
November 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
October 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
October 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 26, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
October 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
October 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
September 16, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
September 12, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate at September Investor Conferences
August 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
July 01, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
June 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
May 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
May 25, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
April 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 20, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
February 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.